Open-Label Extension Protocol to SNK01-AD01 Study
Recruiting
Phase 2
Interventional Study
Alzheimer Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 – 85
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- NKGen Biotech, Inc. · Industry
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Open-Label Extension Protocol to SNK01-AD01 Study
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Participants will be considered eligible for participation in the study if all the following criteria are satisfied:
* The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements …
Contacts